Trust Co. of Toledo NA OH Has $541,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Trust Co. of Toledo NA OH increased its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 19.5% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 6,939 shares of the company’s stock after acquiring an additional 1,133 shares during the period. Trust Co. of Toledo NA OH’s holdings in AstraZeneca were worth $541,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock worth $4,151,177,000 after purchasing an additional 9,002,450 shares in the last quarter. Sanders Capital LLC grew its holdings in shares of AstraZeneca by 39.0% during the 4th quarter. Sanders Capital LLC now owns 14,684,066 shares of the company’s stock worth $988,972,000 after purchasing an additional 4,122,965 shares in the last quarter. Swedbank AB acquired a new stake in shares of AstraZeneca during the 1st quarter worth approximately $186,127,000. Norges Bank acquired a new stake in shares of AstraZeneca during the 4th quarter worth approximately $143,999,000. Finally, Clearbridge Investments LLC grew its holdings in shares of AstraZeneca by 118.9% during the 4th quarter. Clearbridge Investments LLC now owns 3,592,447 shares of the company’s stock worth $241,951,000 after purchasing an additional 1,951,591 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.1 %

Shares of NASDAQ AZN traded down $0.08 during midday trading on Tuesday, hitting $79.25. The stock had a trading volume of 5,683,560 shares, compared to its average volume of 5,365,379. The company’s 50-day simple moving average is $78.74 and its 200 day simple moving average is $72.54. The firm has a market cap of $245.72 billion, a P/E ratio of 38.85, a price-to-earnings-growth ratio of 1.55 and a beta of 0.45. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $82.01. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.89 and a quick ratio of 0.69.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Thursday, July 25th. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.98 by $0.01. The company had revenue of $12.45 billion during the quarter, compared to analysts’ expectations of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same period last year, the firm earned $1.08 EPS. Research analysts anticipate that AstraZeneca PLC will post 4.05 EPS for the current year.

AstraZeneca Cuts Dividend

The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, September 9th. Investors of record on Friday, August 9th will be paid a dividend of $0.49 per share. The ex-dividend date is Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 94.61%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, April 16th. Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. BMO Capital Markets raised their target price on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. The Goldman Sachs Group began coverage on AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price for the company. Finally, Argus lifted their price objective on AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca has an average rating of “Buy” and a consensus target price of $88.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.